Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brilaroxazine - Reviva Pharmaceuticals

Drug Profile

Brilaroxazine - Reviva Pharmaceuticals

Alternative Names: RP 5000; RP-5063

Latest Information Update: 18 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Reviva Pharmaceuticals
  • Class Antidepressants; Antifibrotics; Antipsychotics; Behavioural disorder therapies; Benzoxazines; Chlorobenzenes; Ethers; Ketones; Mood stabilisers; Piperazines; Small molecules
  • Mechanism of Action Dopamine D2 receptor partial agonists; Dopamine D3 receptor partial agonists; Dopamine D4 receptor partial agonists; Serotonin 1A receptor partial agonists; Serotonin 2A receptor partial agonists; Serotonin 6 receptor antagonists; Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Schizophrenia
  • Phase II Schizoaffective disorder
  • Phase I Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension
  • No development reported Attention-deficit hyperactivity disorder; Bipolar disorders; Major depressive disorder; Psychotic disorders
  • Discontinued Autistic disorder; Gilles de la Tourette's syndrome

Most Recent Events

  • 14 Nov 2022 Reviva Pharmaceuticals plans phase IIa clinical trial in Bipolar disorder, Major depressive disorder (MDD), Attention deficit and disruptive behaviour disorders (ADHD), Pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), in 2023 (PO)
  • 31 Oct 2022 Phase-III clinical trials in Schizophrenia in Bulgaria (PO) (EudraCT2021-004193-64)
  • 31 Oct 2022 Reviva Pharmaceuticals receives regulatory approval to conduct phase III RECOVER study for Schizophrenia in India
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top